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Introduction
             Vasovagal syncope is a common condition, usually associated with a benign prognosis. 
Most sufferers experience only occasional symptoms, and can be treated with reassurance and 
lifestyle advice. However, a minority of patients are debilitated by frequent fainting that can 
infringe on daily living, or even mimic sudden death. This has been termed "malignant" 
vasovagal syncope because of the associated falls and physical injury. In these cases, a more 
interventional   approach   may   be   appropriate.                                                          
            Pharmacological measures have been the mainstay of treatment for recurrent vasovagal 
syncope: beta-blockers (e.g. atenolol), serotonin reuptake inhibitors (e.g. paroxetine), certain 
vasoconstricting drugs (e.g. midodrine) and fluid retaining agents (e.g. fludrocortisone) have 
been of particular interest. However, there is only mixed support from randomised controlled 
trials for the efficacy of these agents in preventing vasovagal syncope. 1-3                           
            In the last few years, cardiac pacing has been advocated for the treatment of some forms 
of vasovagal syncope. This article reviews the literature and discusses the indications for pacing 
in   vasovagal   syncope.                                                                          
Rationale   for   pacing                                                                      
             Vasovagal syncope results from transient dysfunction of autonomic cardiovascular 
regulation. Haemodynamic collapse, resulting in either syncope or presyncope, may be induced 
on tilt table testing. The most readily quantifiable physiological responses are vasodepression 
(arterial blood pressure fall) and cardioinhibition (heart rate fall). Cardiac pacing aims to 
overcome bradycardia during syncope and provide enough heart rate support to compensate for 
the   hypotension.                                                                            
Evidence   for   pacing                                                                      
Temporary   pacing   studies                                                                                
            Since the early 1990s, pacing has been an accepted treatment for selected patients with 
vasovagal syncope by both the British Pacing Electrophysiology Group and American Heart 
Association/American College of Cardiology guidelines.4,5 These recommendations were based 
on the results of several non-randomised observational studies. These studies generally indicated 
a beneficial role for temporary pacing during tilt table testing6,7 Some investigators, such as Sra 
et al.8, reported results that could be interpreted as negative because pacing failed to consistently 
abort syncope, although many patients (18 of 22) who initially had syncope had only presyncope 
on   repeat   testing.                                                                    
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Non-randomised studies with permanent pacing                                                       
             Following these initial investigations, evidence to support the use of permanent 
pacemakers in vasovagal syncope came with the publication of three studies which used 
historical controls (Table 1).9-12  Dual-chamber pacemakers were implanted in a total of 77 
patients, the majority of whom had demonstrated bradycardia on tilt table induced syncope. 
These studies consistently showed that after insertion of a permanent pacemaker, most patients 
either no longer had syncope or had far fewer episodes of syncope. 
Table 1. Non-randomised studies with permanent pacing
Randomised  studies   with   permanent  pacing                                                         
            More recently support for a beneficial role for pacing has come from three randomised 
controlled studies (Table 2). Patients were selected if they had a positive tilt table test with a 
predefined severity of bradycardia. The first Vasovagal Pacemaker Study (VPS 1)13 included a 
more highly symptomatic population than either the Vasovagal Syncope International Study 
(VASIS)14 or the Syncope Diagnosis and Treatment Study15: 6 attacks per year versus 3 attacks 
in 2 years. In VPS 1, patients were randomised either to receive a pacemaker with automatic rate 
drop responsiveness or to receive optimal medical therapy as determined by the treating 
physician. The study was designed to enroll 248 patients but was stopped when the interim 
analysis of 54 patients fulfilled the predefined criteria for early termination on the grounds of 
efficacy. There was a significant reduction in the time to first recurrence of syncope in those 
allocated   to   pacing   compared   with   medical   therapy   (22%   vs   70%;   P=0.0002).  
             VASIS   compared   dual-chamber   pacing   with   rate   hysteresis   with   no   pacemaker 
implantation. During a mean follow-up period of 3.7±2.2 years, there was a lower rate of 
recurrent syncope in the pacemaker arm than in the no-pacemaker arm (5% vs 61%; P=0.0006). 
             The Syncope Diagnosis and Treatment Study assessed whether dual-chamber pacing 
with rate drop response or atenolol best prevented vasovagal syncope. All patients were older 
than 35 years, had >3 syncopal episodes in the preceding 2 years, and had a positive tilt table test 
with a bradycardia less than 60 bpm. The study was stopped after the first interim analysis of 
efficacy because those randomised to a pacemaker fainted less frequently than those randomised 
to   atenolol   (4%   vs   26%;   P=0.004).                                                            
         In summary, these three studies showed that, in carefully selected patients, pacing is 
beneficial.   However,   as   these   were   open-label   studies,   a   placebo   effect   of   pacemaker 
implantation cannot be excluded. The ongoing second Vasovagal Pacemaker Study (VPS II) is a 
multinational randomised clinical trial that will enroll 100 patients over three years and will 
address whether dual-chamber pacing with rate drop sensing is superior to placebo. Patients are 
eligible if they have had six or more syncopal episodes and a positive tilt table test, although 
development of bradycardia is not an essential requirement for inclusion. All patients receive a 
dual-chamber pacemaker with rate drop capabilities; half are randomised to rate drop sensing, 
the other half are randomised to a mode which senses and records heart rate periods but does not 
pace. The primary outcome is the first recurrence of syncope. Patients may then enter a second 
phase in which they are randomised to pacing with or without rate drop sensing. Enrolment 
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closed in October 2001, and results are anticipated to be available by late 2002.
Table 2. Randomised trials with permanent pacing
The optimal mode for sensing vasovagal syncope onset                                                       
            Early detection of impending vasovagal syncope is a key factor in the development of an 
effective pacing strategy. Unlike other conditions requiring pacing, the fall in heart rate during 
vasovagal syncope is often insidious rather than abrupt. Pacemakers with a rate drop response 
algorithm are therefore considered particularly appropriate as they take account of the rate of 
fall, as opposed to the more conventional rate hysteresis systems that pace when a particular 
heart rate is reached. In a randomised trial, Ammirati et al. compared rate drop responsiveness 
and rate hysteresis in 20 patients with recurrent syncope.16 This study demonstrated a benefit for 
those with rate drop responsiveness (0/12 fainted) compared with rate hysteresis (3/8 fainted). 
The second phase of VPS II hopes to establish whether dual-chamber pacing with rate drop 
sensing  is superior  to  dual-chamber  pacing at an escape rate  of 50  beats  per minute.
             Further refinement in the ability to detect incipient syncope may arise from the 
recognition of other sensing strategies, such as changes in the QT interval, right ventricular 
pressure, central venous temperature or changes in respiratory pattern. Minute volume sensing 
together with heart rate change may offer earlier detection of impending vasovagal syncope than 
can heart rate alone.17 Pacemakers with this facility are now available, and could prove to be a 
significant adjunct to current sensing modes.                                                           
The optimal mode for pacing in vasovagal syncope                                                     
            Early studies showed single-chamber ventricular demand pacing (VVI) to be ineffective 
in preventing vasovagal syncope.7,18  The absence of atrioventricular synchrony appears to 
aggravate the peripheral vasodilatation, perhaps by retrograde activation of atria and release of 
natruretic peptides. Invasive haemodynamic studies have demonstrated that dual-chamber pacing 
achieves a reduction in the rate of fall of arterial pressure as heart rate drops, which in the 
clinical setting may sufficiently prolong consciousness to allow injury to be avoided.6,7 McLeod 
et al. assessed the relative usefulness of single-chamber pacing (VVI) and dual-chamber pacing 
(DDD) in the prevention of vasovagal syncope in 12 highly symptomatic young children.19 In a 
three way, double blind randomised crossover design, the pacemakers were programmed to no 
pacing,   ventricular   pacing   with   rate   hysteresis,   or   dual-chamber   pacing   with   rate   drop 
responsiveness. Each treatment exposure lasted 4 months. Both pacing modes were equivalent, 
and more effective than no pacing, in preventing syncope. DDD pacing was superior to VVI 
pacing in preventing presyncope. Dual-chamber pacing has now been clinically assessed in 
randomised trials of pacing in vasovagal syncope, and is generally considered to be the pacing 
mode of choice (Table 3).13-15 However, the  optimal  pacemaker  intervention  rate  is  still  the 
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subject of debate. It has been suggested that high rate intervention ( >120 beats/min ) may be 
better than standard rate pacing (80-90 beats/min) in improving symptoms and/or aborting 
syncope.20
Table 3. Studies comparing sensing and pacing modes 
Selecting patients with vasovagal syncope for pacing                                                         g 
            The crucial issue is to identify individuals who could benefit from pacing. Pacemakers 
should be considered for patients with frequent and medically refractory vasovagal syncope in 
whom   there   is   evidence   for   bradycardia.   Patients   with   specific   drug   intolerances   or 
contraindications may be considered earlier. The VASIS group proposed a classification of the 
haemodynamic collapse patterns seen on tilt testing for the purpose of identifying potential 
candidates for drug or pacemakers trials (Table 4).21 Patients with predominant bradycardia 
(cardioinhibition) are the target for pacing. Within this group there is further subdivision into 
more severe or less severe forms. The expectation is that those with the more severe form will 
derive the greatest benefit from pacing. However, there is concern with pacing this group as it 
appears that more severe cardioinhibition is more prevalent in the younger population. Pacing 
young people has a considerable long-term burden, not least of which is the need for periodic 
system replacement. The other group that may benefit from pacing are those with chronotropic 
incompetence. This usually affects a much older population, so there is less reluctance to pace 
these patients. More recently, data from the International Study on Syncope of Uncertain 
Etiology suggests that the spontaneous syncopal event may be the result of a more severe 
bradycardia than that reproduced during tilt testing.22 Hence, more patients may benefit from 
pacing than predicted by tilt testing. These findings need to be supported by further studies. 
Combination   therapy                                                                      
             Cardiac pacing cannot address the profound vasodilatation that occurs together with 
cardioinhibition in vasovagal syncope. Therefore, pacing should not be seen in isolation or 
always as an alternative to pharmacological intervention. Recently, there has been interest in a 
combined approach, using pharmacological support for the vasodepressor component and pacing 
for the cardioinhibitory component - for example, fludrocortisone to minimise intravascular 
volume depletion and pacing to modify the heart rate response. Novel therapies, such as local 
drug delivery systems, may alter the role of pacing or even supersede pacing for vasovagal 
syncope. In a small study, Giada et al. assessed an implantable device that delivers intravenous 
phenylephrine   when   activated   at   the   onset   of   syncope   (prodromal   symptoms   with 
hypotension).23 Tilt-induced syncope was aborted in 94% of treated patients, but not at all when 
a   placebo   was   delivered.   In   the   future,   with   greater   understanding   of   the   underlying 
pathophysiology, the appropriate treatment may be tailored to the individual patient.
Conclusion
            Patients with frequent fainting have a poor quality of life. There is increasing evidence 
that pacing can prevent or delay fainting in selected patients with medically refractory vasovagal 
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syncope. Those with absolute or relative bradycardia on tilt table testing are most likely to 
benefit. Dual-chamber pacing with a rate drop response algorithm appears to be the optimal 
protocol. On-going trials will clarify unresolved issues of how and when to pace.  
Table 4. VASIS classification of positive responses to tilt testing
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